Description

Clinical Evidence

• A 2020 study in JACC: Heart Failure showed SS-31 improved left ventricular function and mitochondrial respiration in patients with heart failure with reduced ejection fraction.
• In models of age-related macular degeneration (AMD), SS-31 preserved retinal structure and mitochondrial health.
• Nature Communications (2019) highlighted SS-31’s ability to reverse age-related mitochondrial dysfunction and improve exercise capacity in aged mice.
• Clinical trials are ongoing in Barth Syndrome, primary mitochondrial myopathy, and chronic kidney disease (CKD), with encouraging early data on safety and efficacy.
SS-31 is unique among therapeutic peptides due to its strong mitochondrial selectivity and ability to cross lipid membranes without a carrier.

Potential Side Effects

In clinical and animal studies, SS-31 has shown a favorable safety profile, with minimal adverse effects. Observed or reported effects include:
• Temporary injection site discomfort
• Mild gastrointestinal symptoms (nausea, cramping) at higher doses
• No reported mitochondrial toxicity or genotoxicity
Tolerability has been excellent in both short-term and long-term research protocols, even in vulnerable populations.

Disclaimer

SS-31 is for laboratory research use only. It is not approved for human consumption or clinical use outside of authorized investigational trials. The data presented reflects preclinical and early-stage human research, and this product must be used only by trained professionals in controlled laboratory environments.